NCT02035267View on ClinicalTrials.gov

Safety Study of ATX-101 (Deoxycholic Acid) in Subjects With Mild or Extreme Fullness of Submental Fat

PHASE3CompletedINTERVENTIONAL
Enrollment

93

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Moderate to Severe Convexity of Submental FatSafetyEfficacy
Interventions
DRUG

Deoxycholic Acid

Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.

DRUG

Placebo

Phosphate buffered saline placebo for injection.

Trial Locations (8)

20769

Glenn Dale

33146

Coral Gables

90069

West Hollywood

Unknown

Newport Beach

San Francisco

Boca Raton

St Louis

02467

Chestnut Hill

Sponsors
All Listed Sponsors
lead

Kythera Biopharmaceuticals

INDUSTRY

NCT02035267 - Safety Study of ATX-101 (Deoxycholic Acid) in Subjects With Mild or Extreme Fullness of Submental Fat | Biotech Hunter | Biotech Hunter